MX2016012481A - Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. - Google Patents

Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.

Info

Publication number
MX2016012481A
MX2016012481A MX2016012481A MX2016012481A MX2016012481A MX 2016012481 A MX2016012481 A MX 2016012481A MX 2016012481 A MX2016012481 A MX 2016012481A MX 2016012481 A MX2016012481 A MX 2016012481A MX 2016012481 A MX2016012481 A MX 2016012481A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
compositions
methods
disease
trka kinase
Prior art date
Application number
MX2016012481A
Other languages
English (en)
Inventor
Chun Sing Li
Harold B Wood
Mitchell Helen
Mao Qinghua
Qi Zhiqi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016012481A publication Critical patent/MX2016012481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se dirige a compuestos heteroaril benzamida bicíclicos de fórmula (I) (ver Fórmula) que son inhibidores de la proteína quinasa de la familia quinasa relacionada con tropomiosina (Trk), y por lo tanto son útiles en el tratamiento del dolor, inflamación, cáncer, restenosis, aterosclerosis, psoriasis, trombosis, una enfermedad, trastorno, lesión, o mal funcionamiento en relación con dismielinación o desmielinación o una enfermedad o trastorno asociado con actividades anormales del receptor TrkA del factor de crecimiento nervioso (NGF).
MX2016012481A 2014-03-26 2015-03-23 Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. MX2016012481A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074143 WO2015143652A1 (en) 2014-03-26 2014-03-26 TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
PCT/US2015/021952 WO2015148354A2 (en) 2014-03-26 2015-03-23 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Publications (1)

Publication Number Publication Date
MX2016012481A true MX2016012481A (es) 2016-12-16

Family

ID=54193893

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012481A MX2016012481A (es) 2014-03-26 2015-03-23 Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.
MX2016012483A MX2016012483A (es) 2014-03-26 2015-03-23 Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016012483A MX2016012483A (es) 2014-03-26 2015-03-23 Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.

Country Status (10)

Country Link
US (2) US9862716B2 (es)
EP (2) EP3122344B1 (es)
JP (2) JP2017508766A (es)
KR (2) KR20160131119A (es)
CN (2) CN106456582A (es)
AU (2) AU2015236438A1 (es)
CA (2) CA2942817A1 (es)
MX (2) MX2016012481A (es)
RU (2) RU2016141645A (es)
WO (3) WO2015143652A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418615B (zh) * 2015-12-09 2018-02-02 北京工业大学 苯甲酰胺衍生物及制备和应用
WO2018236856A1 (en) * 2017-06-19 2018-12-27 University Of Maryland, Baltimore CAR ACTIVATING AGENTS FOR THE TREATMENT OF CANCER BASED ON CYCLOPHOSPHAMIDE
WO2019070943A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20200099557A (ko) * 2017-12-15 2020-08-24 피라미드 바이오사이언스, 인크. 암을 치료하기 위한 Trk 키나제 저해제로서의 5-(2-(2,5-다이플루오로페닐)피롤리딘-1-일)-3-(1H-피라졸-1-일)피라졸로[1,5-a]피리미딘 유도체 및 관련 화합물
MX2020010671A (es) 2018-04-12 2020-10-28 Bayer Ag Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-11-[1-(pirim idin-2-il)-1h-1,2,4-triazol-5-il] etilibenzamida y los derivados de piridinacarboxamida correspondientes como plaguicidas.
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
BR112021003098A2 (pt) * 2018-08-22 2021-05-11 Cullgen (Shanghai), Inc. compostos de degradação de receptor de tropomiosina quinase (trk) e métodos de uso
CN111269233A (zh) * 2018-12-05 2020-06-12 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
TW202134226A (zh) 2019-11-18 2021-09-16 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB599834A (en) * 1943-04-08 1948-03-22 Francolor Sa Improvements in or relating to the manufacture of azodyestuffs
KR100315837B1 (ko) * 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE19946322A1 (de) 1999-09-28 2001-03-29 Bayer Ag Verfahren zur Konditionierung von Ionenaustauscherharzen
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
WO2001081345A1 (fr) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
KR100713137B1 (ko) * 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
EA007430B1 (ru) * 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
US20030144518A1 (en) * 2001-12-07 2003-07-31 The Procter & Gamble Company Process for preparing 3-acylamino-imidazo[1,2-a]pyridines
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
RS20050789A (sr) 2003-05-01 2008-04-04 Bristol-Myers Squibb Company, Aril-supstituisana jedinjenja pirazol-amida pogodna za primenu kao inhibitori kinaze
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
WO2005030128A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
MX2007009842A (es) 2005-02-16 2007-08-23 Astrazeneca Ab Compuestos quimicos.
JP2008540335A (ja) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CN101287707A (zh) 2005-10-13 2008-10-15 德福根有限公司 激酶抑制剂
US20090163549A1 (en) 2005-12-15 2009-06-25 Hiroyuki Kai Pharmaceutical Composition Comprising an Amide Derivative
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101678007B (zh) 2007-04-06 2013-07-03 纽罗克里生物科学有限公司 促性腺激素释放激素受体拮抗剂及其制药用途
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
PT2197849E (pt) 2007-10-09 2013-04-23 Merck Patent Gmbh Derivados de n-(pirazole-3-il)-benzamida como ativadores de glucoquinase
CN103965200B (zh) 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
KR101048448B1 (ko) * 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
US20130017188A1 (en) * 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CN110483499A (zh) * 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
KR101759759B1 (ko) 2010-07-02 2017-07-19 길리애드 사이언시즈, 인코포레이티드 세포자멸사 신호-조절 키나아제 저해제
RU2013109143A (ru) * 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
RS53519B1 (en) 2010-09-01 2015-02-27 Bayer Intellectual Property Gmbh N- (TETRAZOL-5-IL) - AND N- (TRIAZOL-5-IL) aryl amides of carboxylic acid and their use as herbicides
WO2012044090A2 (ko) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
US9079859B2 (en) 2011-01-21 2015-07-14 Auckland Uniservices Limited Synthetic lethal targeting of glucose transport
EA201300894A1 (ru) 2011-02-09 2014-01-30 Зингента Партисипейшнс Аг Инсектицидные соединения
RU2606131C2 (ru) 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
SI2714668T1 (sl) 2011-05-23 2017-06-30 Merck Patent Gmbh Tiazolni derivati
EP2731439A4 (en) * 2011-07-12 2014-12-03 Merck Sharp & Dohme TrkA KINASE INHIBITORS, COMPOSITIONS CONTAINING SAME, AND ASSOCIATED METHODS
KR20140128946A (ko) * 2011-11-14 2014-11-06 테사로, 인코포레이티드 특정한 티로신 키나제의 조절
EP2791139B1 (en) * 2011-12-12 2017-11-08 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑

Also Published As

Publication number Publication date
CN106456581A (zh) 2017-02-22
US9862716B2 (en) 2018-01-09
US20170114056A1 (en) 2017-04-27
RU2016141645A3 (es) 2018-10-26
WO2015148373A3 (en) 2015-11-26
WO2015148354A2 (en) 2015-10-01
CA2942817A1 (en) 2015-10-01
RU2016141645A (ru) 2018-04-27
WO2015148354A3 (en) 2015-12-03
CA2942957A1 (en) 2015-10-01
WO2015148373A2 (en) 2015-10-01
RU2016141647A3 (es) 2018-06-26
AU2015236438A1 (en) 2016-09-01
CN106456582A (zh) 2017-02-22
US9862707B2 (en) 2018-01-09
MX2016012483A (es) 2016-12-16
RU2016141647A (ru) 2018-04-27
JP2017508766A (ja) 2017-03-30
KR20160132114A (ko) 2016-11-16
AU2015236363A1 (en) 2016-09-01
WO2015143652A1 (en) 2015-10-01
EP3122345B1 (en) 2020-12-16
EP3122345A4 (en) 2017-10-04
EP3122344B1 (en) 2022-04-27
EP3122344A4 (en) 2017-09-06
US20170107204A1 (en) 2017-04-20
EP3122344A2 (en) 2017-02-01
WO2015143652A8 (en) 2015-12-10
KR20160131119A (ko) 2016-11-15
JP2017512786A (ja) 2017-05-25
EP3122345A2 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
MX2016012483A (es) Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.
MX2016012480A (es) Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.
WO2015042085A3 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015148350A3 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
WO2016164286A3 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
SG10201806846RA (en) Cyclopropylamines as lsd1 inhibitors
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
NZ721057A (en) Compositions of compounds and uses thereof
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112017008039A2 (pt) derivados de pirazol como inibidores de nik
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2017000524A (es) Compuestos novedosos de pirimidina sustituida.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112017007704A2 (pt) derivados de pirazolopirimidina como inibidores de nik
TW201613896A (en) Novel 2,5-substituted pyrimidines
MX366840B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.